Axogen to Participate at Upcoming Investor Conferences
04 November 2022 - 7:00AM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today announced that Karen Zaderej, chairman, CEO, and
president, and Peter Mariani, executive vice president and CFO will
participate in upcoming investor conferences in November and
December.
- Zaderej will participate in a fireside
chat at the Jefferies London Healthcare Conference, on Tuesday,
November 15, 2022 at 10:20 a.m. GMT, (5:20 a.m. ET).
- Mariani will participate in a fireside
chat at the Canaccord Genuity MedTech, Diagnostics and Digital
Health & Services Forum in New York City on Thursday, November
17, 2022 at 8:30 a.m. ET.
- Zaderej will present at the Piper
Sandler 34th Annual Healthcare Conference in New York City on
Wednesday, November 30, 2022 at 10:30 a.m. ET.
- Zaderej and Mariani will participate
in a panel discussion at the Cantor Medical & Aesthetic
Dermatology, Ophthalmology & Medtech Conference in Miami, on
Thursday, December 8, 2022 at 2:45 p.m. ET.
Webcasted events can be accessed live through the Investors page
at www.axogeninc.com. For those not available to listen to the live
broadcasts, replays will be archived for 90 days and available
through the Investors page on www.axogeninc.com.
About AxogenAxogen (AXGN) is
the leading company focused specifically on the science,
development, and commercialization of technologies for peripheral
nerve regeneration and repair. Axogen employees are passionate
about helping to restore peripheral nerve function and quality of
life to patients with physical damage or transection to peripheral
nerves by providing innovative, clinically proven, and economically
effective repair solutions for surgeons and health care providers.
Peripheral nerves provide the pathways for both motor and sensory
signals throughout the body. Every day, people suffer traumatic
injuries or undergo surgical procedures that impact the function of
their peripheral nerves. Physical damage to a peripheral nerve, or
the inability to properly reconnect peripheral nerves, can result
in the loss of muscle or organ function, the loss of sensory
feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair
features a comprehensive portfolio of products, including Avance®
Nerve Graft, a biologically active off-the-shelf processed human
nerve allograft for bridging severed peripheral nerves without the
comorbidities associated with a second surgical site; Axoguard
Nerve Connector®, a porcine submucosa extracellular matrix (ECM)
coaptation aid for tensionless repair of severed peripheral nerves;
Axoguard Nerve Protector®, a porcine submucosa ECM product used to
wrap and protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; and
Axoguard Nerve Cap®, a porcine submucosa ECM product used to
protect a peripheral nerve end and separate the nerve from the
surrounding environment to reduce the development of symptomatic or
painful neuroma. The Axogen portfolio of products is available in
the United States, Canada, Germany, the United Kingdom, Spain,
South Korea, and several other countries.
Contact:Axogen, Inc.Ed Joyce, Director,
Investor Relationsejoyce@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024